Perspective Therapeutics (NYSE:CATX) Given Outperform Rating at Wedbush

Perspective Therapeutics (NYSE:CATX - Get Free Report)'s stock had its "outperform" rating reissued by stock analysts at Wedbush in a research note issued to investors on Thursday, Benzinga reports. They currently have a $20.00 price objective on the stock. Wedbush's price objective suggests a potential upside of 68.21% from the stock's current price.

A number of other research analysts have also weighed in on the stock. Truist Financial assumed coverage on shares of Perspective Therapeutics in a research note on Wednesday, September 25th. They issued a "buy" rating and a $21.00 price objective on the stock. Bank of America began coverage on shares of Perspective Therapeutics in a research report on Thursday, July 25th. They issued a "buy" rating and a $24.00 price target on the stock. Oppenheimer reiterated an "outperform" rating and set a $22.00 price target on shares of Perspective Therapeutics in a research note on Friday, October 11th. Royal Bank of Canada lowered their price objective on Perspective Therapeutics from $29.00 to $27.00 and set an "outperform" rating for the company in a research note on Friday, August 16th. Finally, UBS Group began coverage on Perspective Therapeutics in a research report on Thursday. They set a "buy" rating and a $20.00 target price on the stock. Ten research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $20.63.

Perspective Therapeutics Price Performance

Perspective Therapeutics stock traded up $0.20 during midday trading on Thursday, reaching $11.89. The stock had a trading volume of 307,057 shares, compared to its average volume of 687,263. The business has a fifty day moving average price of $13.80. Perspective Therapeutics has a 12 month low of $2.20 and a 12 month high of $19.05.

Perspective Therapeutics (NYSE:CATX - Get Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.04. The firm had revenue of $0.53 million for the quarter. On average, sell-side analysts expect that Perspective Therapeutics will post -0.87 EPS for the current year.

Institutional Trading of Perspective Therapeutics

Hedge funds have recently bought and sold shares of the business. nVerses Capital LLC bought a new position in Perspective Therapeutics during the third quarter valued at $57,000. Victory Capital Management Inc. purchased a new stake in Perspective Therapeutics during the 2nd quarter worth about $117,000. Point72 DIFC Ltd bought a new position in Perspective Therapeutics in the 2nd quarter worth about $118,000. Trueblood Wealth Management LLC bought a new position in Perspective Therapeutics in the 3rd quarter worth about $217,000. Finally, SG Americas Securities LLC purchased a new position in Perspective Therapeutics during the 3rd quarter valued at about $246,000. 54.66% of the stock is currently owned by institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.